98%
921
2 minutes
20
BackgroundArtificial intelligence (AI)-based systems have the potential to increase the efficiency and effectiveness of breast cancer screening programs but need to be carefully validated before clinical implementation.PurposeTo retrospectively evaluate an AI system to safely reduce the workload of a double-reading breast cancer screening program.Material and MethodsAll digital mammography (DM) screening examinations of women aged 40-74 years between August 2021 and January 2022 in Östergötland, Sweden were included. Analysis of the interval cancers (ICs) was performed in 2024. Each examination was double-read by two breast radiologists and processed by the AI system, which assigned a score of 1-10 to each examination based on increasing likelihood of cancer. In a retrospective simulation, the AI system was used for triaging; low-risk examinations (score 1-7) were selected for single reading and high-risk examinations (score 8-10) for double reading.ResultsA total of 15,468 DMs were included. Using an AI triaging strategy, 10,473 (67.7%) examinations received scores of 1-7, resulting in a 34% workload reduction. Overall, 52/53 screen-detected cancers were assigned a score of 8-10 by the AI system. One cancer was missed by the AI system (score 4) but was detected by the radiologists. In total, 11 cases of IC were found in the 2024 analysis.ConclusionReplacing one reader in breast cancer screening with an AI system for low-risk cases could safely reduce workload by 34%. In total, 11 cases of IC were found in the 2024 analysis; of them, three were identified correctly by the AI system at the 2021-2022 examination.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/02841851251356176 | DOI Listing |
Stem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ann Surg Oncol
September 2025
Department of Surgery, Division of Surgical Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Ann Surg Oncol
September 2025
Department of General Surgery, Abdulkadir Yuksel State Hospital, Gaziantep, Turkey.
Breast Cancer Res Treat
September 2025
Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).
Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.